Andere talen Denali Therapeutics Inc.

Aandelen

DNLI

US24823R1059

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
22,39 ^USD	-2,27%		+9,33%	+4,33%

13/06	Pliant Therapeutics, Inc. benoemt Steve Krognes in zijn raad van bestuur	CI
03/06	Denali Therapeutics' enzymvervangingstherapie gekozen voor FDA's START Pilot Programma; aandelen stijgen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors and Chairperson of Audit Committee	13/06
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer	13/06
Denali Therapeutics' Enzyme Replacement Therapy Picked for FDA's START Pilot Program; Shares Rise	03/06
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies	03/06
Denali Therapeutics Inc. Announces FDA Selects DNL126 for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies	03/06
Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	07/05
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial	01/05
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial	01/05
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	03/04
Denali Therapeutics Files Prospectus for Secondary Offering	22/03
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors	01/03
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	27/02
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	27/02
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/02
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Denali Therapeutics Inc.

Aandelen

DNLI

US24823R1059

Andere talen

Filters